Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Lee

Radiation Oncology Spokane Valley, WA Medical Doctor

NPI 1043266810 CMS profile 706618

1204 N Vercler Rd, Ste201, Spokane Valley, WA 99216

Open in the dashboard

General payments

$137,670

231 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

2 holdings reported · through program year 2025

Through program year 2025, Christopher Lee of Spokane Valley, WA is reported in the CMS Open Payments database as having received $137,670 across 231 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,706 81
2024 General $36,742 59
2023 General $29,891 33
2022 General $21,772 24
2021 General $9,901 5
2020 General $17,491 16
2019 General $6,168 13
2020 Ownership $0 1
2019 Ownership $0 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Lee
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Christopher Lee were reported at $15,706. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Christopher Lee Radiation Oncology median Middle half National median
2019 $6,168 $138 $48–$462 $163
2020 $17,491 $79 $26–$262 $114
2021 $9,901 $119 $37–$358 $132
2022 $21,772 $139 $43–$424 $149
2023 $29,891 $167 $57–$473 $160
2024 $36,742 $168 $56–$541 $164
2025 $15,706 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $71,689 57 payments
  2. Myriad Genetic Laboratories, Inc. $63,067 69 payments
  3. AstraZeneca Pharmaceuticals LP $498 12 payments
  4. Telix Pharmaceuticals $296 4 payments
  5. Janssen Biotech, Inc. $170 8 payments
  6. Novartis Pharmaceuticals Corporation $169 8 payments
  7. Galvanize Therapeutics, Inc $145 1 payment
  8. Dendreon Pharmaceuticals LLC $128 5 payments
  9. Medtronic USA, Inc. $125 1 payment
  10. Pfizer Inc. $110 10 payments
  11. Other $1,274 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $64,868 30 payments
  2. Consulting Fee $35,274 27 payments
  3. Honoraria $28,975 17 payments
  4. Travel and Lodging $4,364 21 payments
  5. Food and Beverage $4,173 133 payments
  6. Education $15 1 payment
  7. Current or prospective ownership or investment interest $2 2 payments
Products named General payments · program years 2019–2025
  1. Xofigo $62,094 50 payments
  2. PROLARIS Oncology $44,740 50 payments
  3. Prolaris Gene Expression Analysis Oncology $12,265 12 payments
  4. Nubeqa $9,720 8 payments
  5. BRAC CDx $3,500 3 payments
  6. myRisk $2,562 4 payments
  7. ILLUCCIX Prostate Cancer Diagnosis $296 4 payments
  8. ILLUCCIX Prostate Cancer Therapy $167 3 payments
  9. ALIYA SYSTEM $145 1 payment
  10. IMFINZI $134 5 payments
  11. Other $2,987 124 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record